The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Official Title: Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma
Study ID: NCT01474239
Brief Summary: This randomized, non-comparative study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with recurrent glioblastoma. Patients will be randomized to receive Avastin 10 mg/kg intravenously every 2 weeks or fotemustine 75 mg/m2 on days 1, 8 and 15, followed by, after a 5 weeks interval, 100 mg/m2 intravenously every 3 weeks. Treatment with fotemustine serves as a calibration arm and no formal efficacy comparison will be made between the two treatment arms. The anticipated time of study treatment is until disease progression or unacceptable toxicity.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Napoli, Campania, Italy
, Bologna, Emilia-Romagna, Italy
, Roma, Lazio, Italy
, Genova, Liguria, Italy
, Milano, Lombardia, Italy
, Milano, Lombardia, Italy
, San Giovanni Rotondo, Puglia, Italy
, Terni, Umbria, Italy
, Padova, Veneto, Italy
, Treviso, Veneto, Italy
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR